Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: comparative studies in two laboratories.
about
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trialSusceptibility breakpoints for amphotericin B and Aspergillus species in an in vitro pharmacokinetic-pharmacodynamic model simulating free-drug concentrations in human serum.Rodent Models of Invasive Aspergillosis due to Aspergillus fumigatus: Still a Long Path toward Standardization.Interaction between posaconazole and amphotericin B in concomitant treatment against Candida albicans in vivoPharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosisStandardization of an experimental murine model of invasive pulmonary aspergillosis.Toward more effective antifungal therapy: the prospects of combination therapy.Combination treatment of invasive fungal infections.Posaconazole: clinical pharmacology and potential for management of fungal infections.Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections.Posaconazole: a new broad-spectrum antifungal agent.Combination antifungal therapy: the new frontier.Combination therapeutic approaches for the management of invasive aspergillosis in organ transplant recipients.Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update.Use of posaconazole in the treatment of invasive fungal infections.Posaconazole: when and how? The clinician's view.Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection.Efficacy of posaconazole in a murine model of central nervous system aspergillosis.Posaconazole: a next-generation triazole antifungal.Application of a low molecular weight antifungal protein from Penicillium chrysogenum (PAF) to treat pulmonary aspergillosis in mice.In Vivo Synergy of Amphotericin B plus Posaconazole in Murine Aspergillosis.Evaluation of Antifungal Activity and Mode of Action of New Coumarin Derivative, 7-Hydroxy-6-nitro-2H-1-benzopyran-2-one, against Aspergillus spp.In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis.Challenges in designing animal studies to detect antagonism of polyene activity.Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro.Successful treatment of disseminated mucormycosis with a combination of liposomal amphotericin B and posaconazole in a patient with acute myeloid leukaemia.A new coumarin derivative, 4-acetatecoumarin, with antifungal activity and association study against Aspergillus spp.Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.
P2860
Q28277029-2097F078-ECBE-464C-BFA5-DEB1C7543776Q33622932-91251D8C-07DB-4813-81C8-657750AC117EQ33689767-52A0AA01-0C06-4E00-8300-64C792CF8F0FQ33803508-176158E6-FF13-4871-A26B-16762780A7BBQ34352109-40893EFC-827D-4475-BB65-BC1C4724378EQ35091545-355A0D02-FCDB-4536-8229-37FF182D4AAFQ35828187-A714B064-3F79-4568-B707-DF7F0C8DF17CQ36011378-8C67620B-2E4C-4454-85CB-C6BF1AD17E77Q36233491-27BB8B5D-D163-4E8C-9E37-6FC82E1A290DQ36589297-37BBFFAB-BB56-4A9F-9F82-A5C020A0A385Q36828159-2775AF3E-3AFD-4625-96AE-8CFBC3BC23CAQ36895652-DFBC8D05-6232-4FA9-9F93-F033850DDF92Q37078394-32A53267-EA57-406E-AD99-8E607F903FFDQ37404840-D214D125-FDB0-4182-9CC1-C8E5A8357AD4Q37810083-EC119531-2D3E-410B-812C-E0B1B185F21DQ37901534-347935F2-CC97-4CFD-9D2C-D404B1EAB1D1Q38140015-A121C277-250E-4F90-893B-AE4FB00D0586Q39955190-37C07FA4-382E-4BFB-B0C5-1E031BAE0993Q40164914-F1DAE389-4DC3-40F8-ABBA-B9C666E12D55Q40188974-3FF324B7-DA9C-4CF9-9555-6BE10407EE00Q40459122-121D1469-C645-4EE8-A809-DEB1B213E9B4Q40936437-62C9707D-B305-44B6-8467-8CFCF4BB8661Q41107710-5364E8B5-E460-4902-ACD3-604494026D10Q42107363-E374053E-4189-49DB-B556-DDB6C72068F4Q42409788-BD68C0E1-E4A8-417E-8250-0969CF710802Q42956812-8724F8F8-EEC9-45B9-9D13-4E70D948E47AQ44494625-6AA06097-50F8-4798-96FA-1E3341CD7C2AQ46268916-4240AB4B-6FF4-4034-862A-028035FC2763Q46840248-2BF92713-6DA0-4CB0-9C2F-51F79814FDED
P2860
Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: comparative studies in two laboratories.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Activity of posaconazole combi ...... e studies in two laboratories.
@ast
Activity of posaconazole combi ...... e studies in two laboratories.
@en
type
label
Activity of posaconazole combi ...... e studies in two laboratories.
@ast
Activity of posaconazole combi ...... e studies in two laboratories.
@en
prefLabel
Activity of posaconazole combi ...... e studies in two laboratories.
@ast
Activity of posaconazole combi ...... e studies in two laboratories.
@en
P2093
P2860
P1476
Activity of posaconazole combi ...... e studies in two laboratories.
@en
P2093
Anthony Cacciapuoti
David Loebenberg
Frederick Menzel
John R Graybill
Judith Halpern
Laura K Najvar
Maya Gurnani
Rosie Bocanegra
Steve Hernandez
P2860
P304
P356
10.1128/AAC.48.3.758-764.2004
P407
P577
2004-03-01T00:00:00Z